A groundbreaking study by Dr. Shiksha Gallow, a holistic integrative practitioner and clinical pathologist, has demonstrated that medicinal cannabis can enhance the effectiveness of chemotherapy in treating prostate cancer. The five-year study monitored 90 men over 60 with advanced Stage 4 prostate cancer, who were divided into three treatment groups. The research, which earned Dr. Gallow her doctorate from Durban University of Technology, showed that patients receiving a combination of chemotherapy and medicinal cannabis achieved a 63% rate of tumor reduction or remission.
Dr. Gallow's research faced intense academic scrutiny and multiple publication rejections before being peer-reviewed and published. Despite the challenges, her study provides new insights into the potential benefits of medicinal cannabis in cancer treatment. The research showed that medicinal cannabis not only enhanced chemotherapy effectiveness but also improved bone pain management and quality of life for patients. Dr. Gallow's findings have significant implications for the treatment of prostate cancer and the use of medicinal cannabis in oncology.
The study's results are particularly noteworthy given the limited research on the topic. According to Dr. Gallow, no other research on the specific arrangement of medicinal cannabis and chemotherapy in prostate cancer treatment exists globally. Her study puts South Africa on the map in terms of medical cannabis research and highlights the potential for the plant to be used as a complementary therapy in cancer treatment. Dr. Gallow's work has garnered international attention, with her being invited to speak at conferences worldwide.
Dr. Gallow's journey to completing her research was not without its challenges. She faced criticism from academics and experienced multiple rejections from publications. However, she persevered, driven by her passion for her topic and her commitment to advancing medical knowledge. Her experience in a beauty pageant, where she was encouraged to be quiet about her views on medicinal cannabis, ultimately steered her back to her core role as a researcher.
The study involved monitoring three groups of patients with advanced Stage 4 prostate cancer. One group received only cannabis treatment, another received only chemotherapy, and the third group received a combination of both. The research went beyond simply assessing patients' subjective experiences, instead focusing on the measurable effects of medicinal cannabis on tumor reduction and remission. The study's findings suggest that medicinal cannabis can be a valuable adjunct to chemotherapy in treating prostate cancer.
Dr. Gallow is now advocating for formal medical regulation of medicinal cannabis in South Africa, warning against unregulated commercial products and urging oncologists and practitioners to examine the clinical data. Her research has the potential to inform policy and practice in the field of oncology and medicinal cannabis. As she continues to travel the world sharing her findings, Dr. Gallow remains committed to advancing medical knowledge and improving patient outcomes.
Dr. Gallow's achievement is a testament to her dedication and perseverance. With three master's degrees and three doctorates, she is a highly accomplished researcher and practitioner. Her work on medicinal cannabis and prostate cancer treatment is a significant contribution to the field, and her advocacy for formal medical regulation is crucial in ensuring that patients have access to safe and effective treatments.
Key points
- Dr. Shiksha Gallow's research shows that medicinal cannabis can enhance chemotherapy effectiveness in treating prostate cancer.
- The study's findings have significant implications for the treatment of prostate cancer and the use of medicinal cannabis in oncology.
- Dr. Gallow is advocating for formal medical regulation of medicinal cannabis in South Africa.
